Since trastuzumab is only approved for HER2-positive gastric cancers (6–30%) and approximately 50% of HER2-positive cancers are resistant to trastuzumab treatment, there is an urgent need for alternative therapies (reviewed by [4]). This evidence concerns the gene ERBB2 and cancer.